AT-406, an orally active antagonist of multiple inhibitor of apoptosis proteins, inhibits progression of human ovarian cancer

Proapoptotic Protein Smac Mediates Apoptosis in Cisplatin-resistant Ovarian Cancer Cells When Treated with the Anti-tumor Agent AT101

(2011) Wenbin Hu et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

A Potent and Orally Active Antagonist (SM-406/AT-406) of Multiple Inhibitor of Apoptosis Proteins (IAPs) in Clinical Development for Cancer Treatment

(2011) Qian Cai et al.   JOURNAL OF MEDICINAL CHEMISTRY

Cancer Statistics, 2010

(2010) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Angiopoietin-4 Promotes Glioblastoma Progression by Enhancing Tumor Cell Viability and Angiogenesis

(2010) M. K. Brunckhorst et al.   CANCER RESEARCH

Downregulation of HtrA1 Promotes Resistance to Anoikis and Peritoneal Dissemination of Ovarian Cancer Cells

(2010) X. He et al.   CANCER RESEARCH

CD44 Attenuates Activation of the Hippo Signaling Pathway and Is a Prime Therapeutic Target for Glioblastoma

(2010) Y. Xu et al.   CANCER RESEARCH

Smac mimetics increase cancer cell response to chemotherapeutics in a TNF-α-dependent manner

(2010) B L Probst et al.   CELL DEATH AND DIFFERENTIATION

XIAP gene downregulation by small interfering RNA inhibits proliferation, induces apoptosis, and reverses the cisplatin resistance of ovarian carcinoma

(2009) Jia-jia Ma et al.   European Journal of Obstetrics & Gynecology and Reproductive Biology

Merlin Is a Potent Inhibitor of Glioma Growth

(2008) Y.-K. I. Lau et al.   CANCER RESEARCH

SM-164: A Novel, Bivalent Smac Mimetic That Induces Apoptosis and Tumor Regression by Concurrent Removal of the Blockade of cIAP-1/2 and XIAP

(2008) J. Lu et al.   CANCER RESEARCH